Recently, KMT2C (MLL3) aberrant promoter methylation was detected in the plasma cfDNA of NSCLC patients at both early and advanced stages, but not in the plasma of healthy individuals [113]. The gene discussed is KMT2C; the disease is non-small cell lung carcinoma.